For latest information on South African COVID-19 Resource Portal go to sacoronavirus.co.za
Toggle Bar

Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines.

Laher, F., Moodie, Z., Cohen, K.W., Grunenberg, N., Bekker, L.G., Allen, M., Frahm, N., Yates, N.L., Morris, L., Malahleha, M. and Mngadi, K., 2020. Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines. PLoS medicine, 17(2), p.e1003038.